Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy

Long-term visual outcome

Hae Min Kang, Hyoung Jun Koh, Christopher Seungkyu Lee, Sungchul Lee

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose To evaluate the long-term visual outcome after combination therapy of photodynamic therapy (PDT) with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy (PCV). Design Retrospective observational study. Methods The medical records of 34 eyes (34 patients) with naïve PCV who were treated with combination therapy were analyzed. All patients completed at least 3 years of follow-up. All clinical data, including age, best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution [logMAR]), imaging data of fluorescein angiography, indocyanine green angiography, and optical coherence tomography, were investigated. Results During a mean follow-up period of 46.8 ± 5.2 months, a mean of 1.4 ± 0.71 times of PDT and 9.2 ± 6.6 intravitreal bevacizumab injections were performed. During follow-up, 21 eyes (61.8%) showed at least 1 recurrence. Mean BCVA was 0.59 ± 0.35 logMAR (20/77 Snellen equivalent) at baseline and 0.39 ± 0.34 logMAR (20/49 Snellen equivalent) at 3 years (P =.004). At 3 years, 14 patients (41.2%) gained 0.3 logMAR or more BCVA and 4 patients (11.8%) lost 0.3 logMAR or more BCVA than baseline. Baseline polyp size (β =.551; P =.005) and location of polyps (β = -.400; P =.033) were significantly correlated with long-term visual outcome after combination therapy for PCV. Conclusions Combination therapy of PDT with intravitreal bevacizumab injections showed favorable visual outcomes, and significant visual improvement was maintained in PCV patients. A total of 88.2% of patients avoided visual loss at 3 years after treatments. Largest polyp size at baseline and location of polypoidal lesions were prognostic factors for long-term visual outcomes in these patients.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume157
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Intravitreal Injections
Photochemotherapy
Polyps
Therapeutics
Indocyanine Green
Fluorescein Angiography
Optical Coherence Tomography
Bevacizumab
Visual Acuity
Medical Records
Observational Studies
Angiography
Retrospective Studies
Recurrence

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{426baf6c308a4fed97f8fdce6a7347d2,
title = "Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: Long-term visual outcome",
abstract = "Purpose To evaluate the long-term visual outcome after combination therapy of photodynamic therapy (PDT) with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy (PCV). Design Retrospective observational study. Methods The medical records of 34 eyes (34 patients) with na{\"i}ve PCV who were treated with combination therapy were analyzed. All patients completed at least 3 years of follow-up. All clinical data, including age, best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution [logMAR]), imaging data of fluorescein angiography, indocyanine green angiography, and optical coherence tomography, were investigated. Results During a mean follow-up period of 46.8 ± 5.2 months, a mean of 1.4 ± 0.71 times of PDT and 9.2 ± 6.6 intravitreal bevacizumab injections were performed. During follow-up, 21 eyes (61.8{\%}) showed at least 1 recurrence. Mean BCVA was 0.59 ± 0.35 logMAR (20/77 Snellen equivalent) at baseline and 0.39 ± 0.34 logMAR (20/49 Snellen equivalent) at 3 years (P =.004). At 3 years, 14 patients (41.2{\%}) gained 0.3 logMAR or more BCVA and 4 patients (11.8{\%}) lost 0.3 logMAR or more BCVA than baseline. Baseline polyp size (β =.551; P =.005) and location of polyps (β = -.400; P =.033) were significantly correlated with long-term visual outcome after combination therapy for PCV. Conclusions Combination therapy of PDT with intravitreal bevacizumab injections showed favorable visual outcomes, and significant visual improvement was maintained in PCV patients. A total of 88.2{\%} of patients avoided visual loss at 3 years after treatments. Largest polyp size at baseline and location of polypoidal lesions were prognostic factors for long-term visual outcomes in these patients.",
author = "Kang, {Hae Min} and Koh, {Hyoung Jun} and Lee, {Christopher Seungkyu} and Sungchul Lee",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ajo.2013.11.015",
language = "English",
volume = "157",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy : Long-term visual outcome. / Kang, Hae Min; Koh, Hyoung Jun; Lee, Christopher Seungkyu; Lee, Sungchul.

In: American Journal of Ophthalmology, Vol. 157, No. 3, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy

T2 - Long-term visual outcome

AU - Kang, Hae Min

AU - Koh, Hyoung Jun

AU - Lee, Christopher Seungkyu

AU - Lee, Sungchul

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose To evaluate the long-term visual outcome after combination therapy of photodynamic therapy (PDT) with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy (PCV). Design Retrospective observational study. Methods The medical records of 34 eyes (34 patients) with naïve PCV who were treated with combination therapy were analyzed. All patients completed at least 3 years of follow-up. All clinical data, including age, best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution [logMAR]), imaging data of fluorescein angiography, indocyanine green angiography, and optical coherence tomography, were investigated. Results During a mean follow-up period of 46.8 ± 5.2 months, a mean of 1.4 ± 0.71 times of PDT and 9.2 ± 6.6 intravitreal bevacizumab injections were performed. During follow-up, 21 eyes (61.8%) showed at least 1 recurrence. Mean BCVA was 0.59 ± 0.35 logMAR (20/77 Snellen equivalent) at baseline and 0.39 ± 0.34 logMAR (20/49 Snellen equivalent) at 3 years (P =.004). At 3 years, 14 patients (41.2%) gained 0.3 logMAR or more BCVA and 4 patients (11.8%) lost 0.3 logMAR or more BCVA than baseline. Baseline polyp size (β =.551; P =.005) and location of polyps (β = -.400; P =.033) were significantly correlated with long-term visual outcome after combination therapy for PCV. Conclusions Combination therapy of PDT with intravitreal bevacizumab injections showed favorable visual outcomes, and significant visual improvement was maintained in PCV patients. A total of 88.2% of patients avoided visual loss at 3 years after treatments. Largest polyp size at baseline and location of polypoidal lesions were prognostic factors for long-term visual outcomes in these patients.

AB - Purpose To evaluate the long-term visual outcome after combination therapy of photodynamic therapy (PDT) with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy (PCV). Design Retrospective observational study. Methods The medical records of 34 eyes (34 patients) with naïve PCV who were treated with combination therapy were analyzed. All patients completed at least 3 years of follow-up. All clinical data, including age, best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution [logMAR]), imaging data of fluorescein angiography, indocyanine green angiography, and optical coherence tomography, were investigated. Results During a mean follow-up period of 46.8 ± 5.2 months, a mean of 1.4 ± 0.71 times of PDT and 9.2 ± 6.6 intravitreal bevacizumab injections were performed. During follow-up, 21 eyes (61.8%) showed at least 1 recurrence. Mean BCVA was 0.59 ± 0.35 logMAR (20/77 Snellen equivalent) at baseline and 0.39 ± 0.34 logMAR (20/49 Snellen equivalent) at 3 years (P =.004). At 3 years, 14 patients (41.2%) gained 0.3 logMAR or more BCVA and 4 patients (11.8%) lost 0.3 logMAR or more BCVA than baseline. Baseline polyp size (β =.551; P =.005) and location of polyps (β = -.400; P =.033) were significantly correlated with long-term visual outcome after combination therapy for PCV. Conclusions Combination therapy of PDT with intravitreal bevacizumab injections showed favorable visual outcomes, and significant visual improvement was maintained in PCV patients. A total of 88.2% of patients avoided visual loss at 3 years after treatments. Largest polyp size at baseline and location of polypoidal lesions were prognostic factors for long-term visual outcomes in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84894047597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894047597&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2013.11.015

DO - 10.1016/j.ajo.2013.11.015

M3 - Article

VL - 157

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -